Phenotypes associated with this allele
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Impdh1tm1Bmi mutation
(0 available);
any
Impdh1 mutation
(23 available)
|
|
|
immune system
|
• decreased lymphocyte proliferation in response to anti-CD3 together with anti-CD28
|
hematopoietic system
|
• decreased lymphocyte proliferation in response to anti-CD3 together with anti-CD28
|
cellular
|
• decreased lymphocyte proliferation in response to anti-CD3 together with anti-CD28
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Impdh1tm1Bmi mutation
(0 available);
any
Impdh1 mutation
(23 available)
Impdh2tm1Bmi mutation
(0 available);
any
Impdh2 mutation
(40 available)
|
|
|
hematopoietic system
|
• decreased lymphocyte proliferation in response to anti-CD3 together with anti-Cd28
|
|
• impairment of splenocyte proliferation also seen in response to concanavalin A, lipopolysaccharide, or to PMA + ionomycin
|
|
• deficient T cell cytolytic effects
|
immune system
|
• decreased lymphocyte proliferation in response to anti-CD3 together with anti-Cd28
|
|
• impairment of splenocyte proliferation also seen in response to concanavalin A, lipopolysaccharide, or to PMA + ionomycin
|
|
• deficient T cell cytolytic effects
|
cellular
|
• decreased lymphocyte proliferation in response to anti-CD3 together with anti-Cd28
|
|
• impairment of splenocyte proliferation also seen in response to concanavalin A, lipopolysaccharide, or to PMA + ionomycin
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hprt1b-m3 mutation
(4 available);
any
Hprt1 mutation
(1274 available)
Impdh1tm1Bmi mutation
(0 available);
any
Impdh1 mutation
(23 available)
|
|
|
hematopoietic system
|
• decreased lymphocyte proliferation due to anti-CD3 + anti-CD28
|
|
• impaired splenocyte proliferation in response to concanavalin A, lipopolysaccharide, or to PMA + ionomycin
|
|
• light but significant drop in proportion of T cells
• fewer cells in S phase
|
|
• deficient T cell cytolytic effect
|
immune system
|
• decreased lymphocyte proliferation due to anti-CD3 + anti-CD28
|
|
• impaired splenocyte proliferation in response to concanavalin A, lipopolysaccharide, or to PMA + ionomycin
|
|
• light but significant drop in proportion of T cells
• fewer cells in S phase
|
|
• deficient T cell cytolytic effect
|
|
• decreased secretion of Il-4 due to decreased GTP levels
• Il-2 levels remain more or less normal
|
cellular
|
• decreased lymphocyte proliferation due to anti-CD3 + anti-CD28
|
|
• impaired splenocyte proliferation in response to concanavalin A, lipopolysaccharide, or to PMA + ionomycin
|